Evidence map›Paper›PMID 34603794›Full record

ArticleJournal of advanced research2021

Activation of TMEM16A Ca

Shuya Luo, Hui Wang, Lichuan Bai, Yiwen Chen, Si Chen, Kuan Gao, Huijie Wang, Shuwei Wu, Hanbin Song, Ke Ma and 4 more

Open access · goldAbstract read
In one paragraph

Article in Journal of advanced research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Three sesquiterpene lactones suppress lung adenocarcinoma by blocking TMEM16A-mediated CaThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2023
    Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Shuya LuoDepartment of Ion Channel Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Hui WangDepartment of Ion Channel Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Lichuan BaiDepartment of Ion Channel Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Yiwen ChenDepartment of Ion Channel Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Si ChenDepartment of Microbial and Biochemical Pharmacy, School of Pharmacy, China Medical University, Shenyang 110122, China.
Kuan GaoDepartment of Ion Channel Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Huijie WangDepartment of Ion Channel Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Shuwei WuDepartment of Ion Channel Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Hanbin SongDepartment of Ion Channel Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Ke MaDepartment of Ion Channel Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Mei LiuDepartment of Ion Channel Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
Fan YaoDepartment of Breast Surgery and Surgical Oncology, Research Unit of General Surgery, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Yue FangDepartment of Microbial and Biochemical Pharmacy, School of Pharmacy, China Medical University, Shenyang 110122, China.
Qinghuan XiaoDepartment of Ion Channel Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Transmembrane protein 16A (TMEM16A) is a Ca Objective: In this study, we investigated whether TMEM16A channel activation by ROCK1/moesin promotes breast cancer metastasis. Methods: Wound healing assays and transwell migration and invasion assays were performed to study the migration and invasion of MCF-7 and T47D breast cancer cells. Western blotting was performed to evaluate the protein expression, and whole-cell patch clamp recordings were used to record TMEM16A Cl Results: TMEM16A activation promoted breast cancer cell migration and invasion Conclusion: Our findings revealed a novel mechanism underlying TMEM16A-mediated breast cancer metastasis, in which ROCK1 increased TMEM16A channel activity via moesin phosphorylation and the increase in TMEM16A channel activities promoted cell migration and invasion. TMEM16A inhibition may be a novel strategy for treating breast cancer metastasis.

Indexed as

Breast NeoplasmsAnimalsCell MovementCell ProliferationFemaleHumansMiceMicrofilament Proteinsrho-Associated KinasesMicrofilament Proteinsmoesinrho-Associated KinasesROCK1 protein, humanCl− channelEGFR, epidermal growth factor receptorER, estrogen receptorFBS, fetal bovine serumH&E, hematoxylin and eosinHNSCC, head and neck squamous cell carcinomaIHC, immunohistochemicalMetastasisMFS, metastasis-free survivalMoesinOS, overall survivalPR, progesterone receptorROCK1ROCK1, Rho-associated, coiled-coil containing protein kinase 1shRNAs, small hairpin RNAsSTAT3, signal transducers and activators of transcription 3TCGA, The Cancer Genome AtlasTMEM16A

Identifiers

PMID34603794
PMCPMC8463928
OpenAlexW3138611680

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.